nephropathy

Climb Bio ascends from Eliem legacy, buying IgA antibody for $9M

Eliem Therapeutics is continuing its transformation into an immune-mediated company by paying $9 million for a Chinese biotech’s preclinical antibody.

James Waldron Jan 9, 2025 10:07am

Analysts hail Vera's kidney drug as potential 'functional cure'

Oct 28, 2024 9:27am

Vertex pays $4.9 billion to hike Alpine’s immunology trail

Apr 10, 2024 5:30pm

flight airplane take off land plane aircraft sky fly

Novartis' $3.2B Chinook bet takes flight as phase 3 hits goal

Oct 30, 2023 8:16am

failure crash no fail rocket cancelled end

Omeros stops kidney disease phase 3 after interim review fail

Oct 16, 2023 8:45am

Alnylam culls 3 programs, including once-touted nephropathy med

Dec 16, 2022 1:52pm